1. Home
  2. Analysis
  3. Ilevro
  4. Jakafi

Ilevro and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ilevro (nepafenac) and Jakafi (ruxolitinib phosphate).

The phase IV clinical study analyzes what interactions people have when they take Ilevro and Jakafi. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Ilevro?

Ilevro has active ingredients of nepafenac. eHealthMe is studying from 1,531 Ilevro users. Check the latest studies of Ilevro.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

On Jul, 10, 2026

18 people who take Ilevro and Jakafi together, and have interactions are studied.

Ilevro and Jakafi drug interactions.

What are the existing conditions these people have? *

  1. Haemochromatosis (body to absorb more iron than usual from food): 4 people, 22.22%
  2. Urination - Painful: 2 people, 11.11%
  3. Infection: 2 people, 11.11%
  4. Athlete's Foot (a fungal infection affecting the skin between the toes): 2 people, 11.11%
  5. Blood Uric Acid Increased: 2 people, 11.11%
  6. Cardiac Failure Congestive: 2 people, 11.11%
  7. Constipation: 2 people, 11.11%
  8. Cough: 2 people, 11.11%
  9. Fever: 2 people, 11.11%
  10. Herpes Zoster: 2 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Ilevro and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ilevro and Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ilevro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ilevro and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Jakafi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on nepafenac and ruxolitinib phosphate (the active ingredients of Ilevro and Jakafi, respectively), and Ilevro and Jakafi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.